SCHEMBL526287

SCHEMBL526287

CCc1cccc(CC)c1NC(=O)c1noc2c1CCc1cnc(Nc3ccc(N4CCN(CCO)CC4)cc3OC)nc1-2

nearest known ligand 0.82

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TTK P33981 19/20 0.82
AURKA O14965 7/20 0.57
PLK1 P53350 4/20 0.57
CCNA2 P20248 3/20 0.57
CDK2 P24941 3/20 0.57
CCNA1 P78396 3/20 0.57
PLK3 Q9H4B4 1/20 0.53
PLK2 Q9NYY3 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10092906 0.94 TTK (0.92) TTKAURKAPLK1CCNA2CDK2
SCHEMBL526085 0.91 TTK (0.82) TTKAURKAPLK1CCNA2CDK2
SCHEMBL15378765 0.90 TTK (1.00) TTKAURKAPLK1CCNA2CDK2
SCHEMBL1558478 0.89 TTK (0.89) TTKAURKAPLK1CCNA2CDK2
SCHEMBL525841 0.89 TTK (0.78) TTKAURKAPLK1CCNA2CDK2
SCHEMBL14990274 0.88 TTK (0.79) TTKAURKAPLK1CCNA2CDK2
SCHEMBL526126 0.87 TTK (0.79) TTKAURKAPLK1PLK3PLK2
SCHEMBL15377897 0.85 TTK (0.89) TTKAURKAPLK1CCNA2CDK2
SCHEMBL12466629 0.85 TTK (0.82) TTKAURKAPLK1CCNA2CDK2
SCHEMBL15377602 0.85 TTK (0.85) TTKAURKAPLK1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9333205-B2 Isoxazolo-quinazolines as modulators of protein kinase activity NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-05-10 US claimed
EP-2598508-B1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES SRL (IT) 2015-04-22 EP claimed
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-06-06 US claimed
US-9333205-B2 Isoxazolo-quinazolines as modulators of protein kinase activity NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-05-10 US disclosed
EP-2598508-B1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES SRL (IT) 2015-04-22 EP disclosed
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-06-06 US disclosed
EP-2598508-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY Nerviano Medical Sciences S.r.l. (IT) 2013-06-05 EP disclosed
WO-2012013557-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY CSNK1A1, RPS6KA1, CSNK2A1 TTK 341/4885AURKA 1595/4885PLK1 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.